Research & Development

Ascletis opens Clinical Development Shanghai Center

Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of its Clinical Development Shanghai Center, signalling the further expansion of R&D capability, especially in Oncology and Non-alcoholic steatohepatitis (NASH).

Bayer to buy remaining stake in BlueRock Therapeutics

Bayer has agreed to acquire the remaining 50.2% interest in US-based biotechnology company BlueRock Therapeutics for around $240m (£197m) in cash.

Vesselon acquires FDA-approved Lipid Microsphere Drug Imagent for therapeutic platform

Vesselon, an oncology therapeutics company, announced the acquisition of an FDA-approved drug Imagent.

Permira to buy small molecule company Cambrex for £1.97bn

An affiliate of investment firm Permira has agreed to acquire small molecule company Cambrex in a deal valued at around $2.4bn (£1.97bn), including its net debt.

GSK grants license for Ebola vaccines to Sabin Vaccine Institute

GSK has granted exclusive technology license for its clinical-stage Ebola vaccines to the Sabin Vaccine Institute, a US-based nonprofit organisation that promotes global vaccine development.

Aquinox to buy biopharmaceutical firm Neoleukin Therapeutics

Aquinox Pharmaceuticals has signed an agreement to acquire biopharmaceutical company Neoleukin Therapeutics.

Antikor Biopharma and Essex Bio-Technology forge strategic alliance in FDC for cancer treatment

Biotechnology company Antikor Biopharma Ltd is pleased to announce that it has entered into an Investment Agreement for up to US$3,100,000 with Essex Bio-Investment, a wholly-owned subsidiary of Essex Bio-Technology Ltd (”EssexBio”), which will enable Antikor to consolidate and expand its position as a leading innovator in smaller-format conjugate therapies for solid tumours.

Kyowa Kirin buys back Tivozanib non-oncology rights from AVEO Oncology

Kyowa Kirin and AVEO Oncology announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU.

Exelixis, Aurigene strike deal to discover and develop novel therapies for cancer

Exelixis, Inc. announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology company focused on oncology and inflammatory disorders.